Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004412 | 0.89 | ALOX15 (0.47) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL9802503 | 0.84 | KDM4E (0.65) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL10263410 | 0.81 | PKN1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL13482827 | 0.81 | KDM4E (0.70) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL21410188 | 0.80 | PKN1 (0.42) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL1005769 | 0.80 | TSHR (0.49) | ALDH1A1KDM4EHPGDHSD17B10PKN1 | |
| SCHEMBL1004852 | 0.77 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL2077218 | 0.77 | BRD4 (0.47) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL8168410 | 0.76 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL20378753 | 0.76 | HSD17B10 (0.54) | ALDH1A1KDM4EHPGDHSD17B10PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| US-12054494-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20220378923-A1 | BET DEGRADER | KYOWA KIRIN CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4039333-A1 | BET DEGRADER | Kyowa Kirin Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2460794-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | HRH4, HRH3, HRH2 | ALDH1A1 4042/4885KDM4E 1101/4885HPGD 1561/4885 |
| US-12054494-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885KDM4E 4107/4885HPGD 3514/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885KDM4E 4107/4885HPGD 3514/4885 |
| US-20220378923-A1 | BET DEGRADER | BET1, BRD4, BICRA | ALDH1A1 3226/4885KDM4E 183/4885HPGD 4524/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885KDM4E 4107/4885HPGD 3514/4885 |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885KDM4E 4107/4885HPGD 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.